Clinical Trial Update: Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies [Phase 1]

View source ↗

Summary

This update describes safety data from a Phase 1 study of AP24534 (ponatinib) in patients with chronic myeloid leukemia and other hematologic malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Hematologic Malignancies

Drugs mentioned

• AP24534 (ponatinib)

Snippet

Sponsor: Ariad Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia, Hematologic Malignancies | Phase 1 | Status: COMPLETED